| Ramon E Rivera, MD | |
|
1514 Jefferson Hwy, New Orleans, LA 70121-2429 | |
| (504) 842-4000 | |
| Not Available |
| Full Name | Ramon E Rivera |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 26 Years |
| Location | 1514 Jefferson Hwy, New Orleans, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457545600 | NPI | - | NPPES |
| 1015628 | Medicaid | LA | |
| 03028845 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD.201651 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaleida Health | Buffalo, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| General Physician Pc | 9537213079 | 333 |
News Archive
Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.
A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital and scientists from Cambridge device maker Pendar Technologies.
› Verified 5 days ago
| Entity Name | Kaleida Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366473183 PECOS PAC ID: 7810805280 Enrollment ID: O20031105000212 |
News Archive
Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.
A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital and scientists from Cambridge device maker Pendar Technologies.
› Verified 5 days ago
| Entity Name | Academic Medicine Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255394763 PECOS PAC ID: 0941105241 Enrollment ID: O20040429000839 |
News Archive
Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.
A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital and scientists from Cambridge device maker Pendar Technologies.
› Verified 5 days ago
| Entity Name | General Physician Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093959322 PECOS PAC ID: 9537213079 Enrollment ID: O20090818000154 |
News Archive
Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.
A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital and scientists from Cambridge device maker Pendar Technologies.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ramon E Rivera, MD 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 | Ramon E Rivera, MD 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 |
News Archive
Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.
A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital and scientists from Cambridge device maker Pendar Technologies.
› Verified 5 days ago
Leigh Victoria Deshotels, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave # Sl50, New Orleans, LA 70112 Phone: -- | |
Dr. James Desporte Lilly, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2820 Napoleon Ave, Suite 720, New Orleans, LA 70115 Phone: 504-896-8670 Fax: 504-896-8699 | |
Carmen Gladys Espinoza, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1542 Tulane Ave, New Orleans, LA 70112 Phone: 504-903-1301 | |
Jose Rodrigo Restrepo, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: Department Of Radiology, 1542 Tulane Ave, Box T2-2, New Orleans, LA 70112 Phone: 504-568-4646 | |
Jorge Alan Martinez, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2021 Perdido St, New Orleans, LA 70112 Phone: 504-903-3000 | |
Dr. Princess Eronmwon Dennar, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave, Sl-16, New Orleans, LA 70112 Phone: 504-988-7518 Fax: 504-988-8252 | |
Eric Edward Holt I, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4747 Earhart Blvd Ste. J, New Orleans, LA 70125 Phone: 504-592-9818 Fax: 504-522-2248 |